Table 7.

Multivariate analysis of factors predictive of FFR for 77 patients treated with rituximab

Freedom from recurrence
Hazards ratio95% confidence intervalP
PCR− vs PCR+ (BM at 12 wk) 0.54 0.18-1.61 .271 
PCR− vs PCR+ (BM at 44 wk) 0.34 0.12-1.00 .049  
Sex (F vs M) 0.17 0.05-0.62 .007  
IPI (0-1 vs ≥ 2) 0.63 0.21-1.87 .403  
Absence of    
 BM infiltration 0.41 0.12-1.38 .151 
 Bulky disease 0.74 0.27-2.02 .555  
 Extranodal sites 0.52 0.10-2.60 .426 
Freedom from recurrence
Hazards ratio95% confidence intervalP
PCR− vs PCR+ (BM at 12 wk) 0.54 0.18-1.61 .271 
PCR− vs PCR+ (BM at 44 wk) 0.34 0.12-1.00 .049  
Sex (F vs M) 0.17 0.05-0.62 .007  
IPI (0-1 vs ≥ 2) 0.63 0.21-1.87 .403  
Absence of    
 BM infiltration 0.41 0.12-1.38 .151 
 Bulky disease 0.74 0.27-2.02 .555  
 Extranodal sites 0.52 0.10-2.60 .426 

For abbreviations, see Table 1.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal